Abstracts tagged "Abatacept and rheumatoid arthritis (RA)"

Abstract Number: 2493 • 2018 ACR/ARHP Annual Meeting
Features of Disease Severity Associated with Patient Satisfaction with Biologic Treatment: Results from the Abatacept Best Care Real-World Study
Boulos Haraoui¹, Janet E. Pope², Emmanouil Rampakakis³, Julie Vaillancourt³, Meryem Maoui⁴ and Louis Bessette⁵, ¹Université de Montréal, Montreal, QC, Canada, ²St. Joseph’s Health Care, London, ON, Canada, ³JSS Medical Research, Montreal, QC, Canada, ⁴Bristol-Myers Squibb, Montreal, QC, Canada, ⁵Laval University, Québec, QC, Canada
Background/Purpose: Patients satisfaction with their treatment is important for adherence to medications, particularly for chronic conditions such as rheumatoid arthritis (RA). The aim of this…
Abstract Number: 2494 • 2018 ACR/ARHP Annual Meeting
Relationship between Specific Joint Involvement and Work/Activity Impairment in Rheumatoid Arthritis Patients: Implications for Clinical Practice
Boulos Haraoui¹, Janet E. Pope², Emmanouil Rampakakis³, Julie Vaillancourt³, Meryem Maoui⁴ and Louis Bessette⁵, ¹Université de Montréal, Montreal, QC, Canada, ²St. Joseph’s Health Care, London, ON, Canada, ³JSS Medical Research, Montreal, QC, Canada, ⁴Bristol-Myers Squibb, Montreal, QC, Canada, ⁵Laval University, Québec, QC, Canada
Background/Purpose: Swelling or tenderness of specific joints may differentially impact the ability of rheumatoid arthritis (RA) patients to perform daily activities and work. The aim…
Abstract Number: 544 • 2018 ACR/ARHP Annual Meeting
Does Anti-Citrullinated Protein Antibody Status Modify Treatment Effect of Certain Biologic DMARDs?
Evo Alemao¹, Yedid Elbez², Yogesh Saini³, Sean E. Connolly¹, Aarti Rao³, Christine K Iannaccone⁴, Michael E Weinblatt⁴ and Nancy A. Shadick⁴, ¹Bristol-Myers Squibb, Princeton, NJ, ²Excelya, Boulogne-Billancourt, France, ³Mu Sigma, Bangalore, India, ⁴Brigham and Women's Hospital, Boston, MA
Background/Purpose: Multiple therapeutic options with different mechanistic actions are available to treat patients (pts) with RA. However, selecting therapies by the characteristics of pts with…
Abstract Number: 1474 • 2017 ACR/ARHP Annual Meeting
A Higher DAS28P, the Subjective Proportion of the DAS28, Predicts a Favorable Response to Abatacept in Rheumatoid Arthritis
Jeong Seok Lee¹, HA Ahmad², Seung-Cheol Shim³, Sang-Cheol Bae⁴, Yeong Wook Song⁵ and Eun Young Lee⁶, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South), ²Bristol-Myers Squibb, Princeton, NJ, ³Division of Rheumatology, Department of Internal Medicine, Daejeon Rheumatoid & Degenerative Arthritis Center, Chungnam National University Hospital, Daejeon, Korea, Republic of (South), ⁴Department of Rhematology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ⁵WCU Department of Molecular Medicine and Biopharmaceutical Sciences, Medical Research Institute, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), ⁶Seoul National University College of Medicine, Seoul, Korea, Republic of (South)
Background/Purpose: Response prediction of certain biologic agents for the treatment of rheumatoid arthritis (RA) is still an unmet need in real-world clinical practice. To reduce…
Abstract Number: 2710 • 2017 ACR/ARHP Annual Meeting
CXCR3+CCR6+CD4+ T Cells (Th1Th17) and RF As Novel Predictive Markers for Clinical Response to Abatacept Treatment in Patients with Rheumatoid Arthritis: The 52-Week Analysis
Koji Mishima¹, Shunichiro Ota², Kazuhiko Higashioka¹, Tsuyoshi Nakayama³, Masahiro Ayano¹, Yasutaka Kimoto⁴, Hiroki Mitoma¹, Mitsuteru Akahoshi¹, Yojiro Arinobu¹, Yasushi Inoue⁵, Kensuke Oryoji⁶, Takuya Sawabe⁷, Shuji Nagano⁸, Hiroaki Nishizaka⁹, Seiji Yoshizawa¹⁰, Shigeru Yoshizawa¹¹, Takeshi Otsuka¹², Akira Ueda¹³, Yoshifumi Tada¹⁴, Hitoshi Nakashima¹⁵, Takahiko Horiuchi¹⁶, Koichi Akashi¹ and Hiroaki Niro³, ¹Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, ²Department of Rheumatology, Shimonoseki City Hospital, Yamaguchi, Japan, ³Department of Medical Education, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan, ⁴Department of Internal Medicine, Kyushu University Beppu Hospital, Oita, Japan, ⁵Department of Rheumatology, Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan, ⁶The Center for Rheumatology, Matsuyama Red Cross Hospital, Ehime, Japan, ⁷Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital, Hiroshima, Japan, ⁸Center for Rheumatology, Iizuka Hospital, Fukuoka, Japan, Iizuka City, Japan, ⁹Kitakyushu Municipal Medical Center, Kitakyushu, Japan, ¹⁰Hamanomachi Hospital, Fukuoka, Japan, ¹¹Department of Rheumatology, Fukuoka Hospital, National Hospital Organization, Fukuoka, Japan, ¹²Munakata Medical Association Hospital, Munakata, Japan, ¹³Department of Internal Medicine, Miyazaki Prefectural Hospital, Miyazaki, Japan, ¹⁴Rheumatology, Saga University, Saga, Japan, ¹⁵Div of Nephrol & Rheumatol, Dept of Int Med, Faculty of Medicine, Fukuoka University, Fukuoka, Japan, ¹⁶Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan
Background/Purpose: The advent of biological therapy has made a remarkable progress in the management of rheumatoid arthritis (RA). Abatacept (ABA), a non-TNF inhibitor, is a…
Abstract Number: 1612 • 2016 ACR/ARHP Annual Meeting
Abatacept Targets T Follicular Helper Cells in Patients with Rheumatoid Arthritis
Shingo Nakayamada¹, Satoshi Kubo², Maiko Yoshikawa², Yusuke Miyazaki², Ippei Miyagawa³, Shigeru Iwata⁴, Kazuhisa Nakano⁵, Kazuyoshi Saito^6,7 and Yoshiya Tanaka⁸, ¹First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁴First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁵The First department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁶The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁷First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, KItakyushu, Japan, ⁸University of Occupational and Environmental Health, Kitakyushu, Japan
Background/Purpose: In the pathogenesis of rheumatoid arthritis (RA), T cells can differentiate into functionally distinct subsets, leading to the persistent inflammation and immune abnormality associated…
Abstract Number: 2538 • 2016 ACR/ARHP Annual Meeting
Comparison of Intravenous Versus Subcutaneous Abatacept for the Treatment of Rheumatoid Arthritis in a Routine Clinical Care Setting: A Preliminary, Time to Response Analysis
Christopher J. Swearingen, Jessica Poon, Hannah Bernstein and Yusuf Yazici, Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: With the availability of multiple biologic agents, each with different modes of action, use of real world registries provide the manner in which to…
Abstract Number: 2612 • 2016 ACR/ARHP Annual Meeting
Sero-Positivity for Rheumatoid Factor Is an Independent Predictor for Achievement of Good EULAR Response at 24 Weeks in ACPA Positive Rheumatoid Arthritis Patients Treated with Abatacept: Results from Japanese Multicenter Registry
Nobunori Takahashi¹, Toshihisa Kojima¹, Shuji Asai¹ and Naoki Ishiguro², ¹Department of Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, ²Nagoya University, Nagoya, Japan
Background/Purpose: Abatacept is a new class of biologic agent for the treatment of rheumatoid arthritis (RA) that inhibits T cell activation by binding to CD80/86.…
Abstract Number: 1093 • 2015 ACR/ARHP Annual Meeting
Activation of Syk-Btk Signal in Peripheral Blood B Cells in Patients with Rheumatoid Arthritis: A Potential Target for Abatacept Therapy
Shigeru Iwata¹, Shingo Nakayamada², Shunsuke Fukuyo¹, Sheau-Pey Wang¹, Satoshi Kubo², Maiko Yoshikawa¹, Kazuyoshi Saito³ and Yoshiya Tanaka³, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
Background/Purpose: B cells play a pivotal role in the pathogenesis of autoimmune diseases. Although Syk function as a key molecule in BCR signaling, the pathological…
Abstract Number: 1674 • 2015 ACR/ARHP Annual Meeting
Predictive Factors of Persistence in Therapy with Abatacept in Patients with Rheumatoid Arthritis
Silvia Piantoni¹, Enrico Colombo¹, Angela Tincani¹, Paolo Airò² and Mirko Scarsi³, ¹Rheumatology and Clinical Immunology Unit, Spedali Civili and University of Brescia, Brescia, Italy, ²Rheumatology and Clinical immunology Unit, Spedali Civili of Brescia, Brescia, Italy, ³Internal Medicine Unit, Esine Vallecamonica Hospital, ASL Vallecamonica-Sebino, Esine, Italy
Background/Purpose: The prediction of a stable treatment for rheumatoid arthritis (RA) is one of the targets of clinical research in rheumatology. However, only few biomarkers…
Abstract Number: 2728 • 2015 ACR/ARHP Annual Meeting
Baseline Characteristics and Changes in Disease Activity at 12 Months in Patients Treated with Abatacept Versus Other Biologic Disease-Modifying Antirheumatic Drugs in Clinical Practice Setting
E Alemao¹, S Joo², M Frits³, C Iannaccone³, N Shadick³ and Michael Weinblatt³, ¹Bristol-Myers Squibb, Princeton, NJ, ²Bristol-Myers Squibb, Hopewell, NJ, ³Brigham and Women's Hospital, Boston, MA
Background/Purpose: Biologic (b)DMARDs have advanced the standard of care in RA, reducing unmet needs and increasing remission rates. Abatacept (ABA) is approved for the management…
Abstract Number: 2764 • 2015 ACR/ARHP Annual Meeting
Head-to-Head Comparison of the Retention Rate of First Biologics in Elderly Patients with Rheumatoid Arthritis in Japanese Clinical Practice: Results from the Multicenter Biologic Registry
Masatoshi Hayashi¹, Toshihisa Kanamono², Hiroyuki Matsubara³, Toshihisa Kojima⁴, Koji Funahashi⁵, Nobunori Takahashi⁴ and Naoki Ishiguro⁶, ¹Departments of Orthopedic surgery and Rheumatology, Nagano Red Cross Hospital, Nagano, Japan, ²Reumatology, Nagano Red Cross Hospital, Nagano, Japan, ³Department of Orthopedic Surgery and Rheumatology, Nagano Red Cross Hospital, Nagano, Japan, ⁴Department of Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, ⁵Nagoya University, Nagoya, Japan, ⁶Department of Orthopedic Suregery, Nagoya University Hospital, Nagoya, Japan
Background/Purpose: The objective of this report was to clarify and compare the retention rate of first biologics used to treat elderly Japanese patients with rheumatoid…
Abstract Number: 2765 • 2015 ACR/ARHP Annual Meeting
Long-Term Retention Rate of First Biologics in Patients of Age over 75 Years with Rheumatoid Arthritis in Japanese Clinical Practice: Results from the Multicenter Biologic Registry
Masatoshi Hayashi¹, Toshihisa Kanamono², Hiroyuki Matsubara³, Toshihisa Kojima⁴, Koji Funahashi⁵, Nobunori Takahashi⁴ and Naoki Ishiguro⁶, ¹Department of Orhtopedic Surgery and Rheumatology, Nagano Red Cross Hospital, Nagano, Japan, ²Reumatology, Nagano Red Cross Hospital, Nagano, Japan, ³Department of Orthopedic Surgery and Rheumatology, Nagano Red Cross Hospital, Nagano, Japan, ⁴Department of Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, ⁵Nagoya University, Nagoya, Japan, ⁶Department of Orthopedic Suregery, Nagoya University Hospital, Nagoya, Japan
Background/Purpose: The objective of this report was to clarify and compare the retention rate of first biologics used to treat elderly Japanese patients with rheumatoid…
Abstract Number: 2778 • 2015 ACR/ARHP Annual Meeting
Abatacept-Treated Rheumatoid Arthritis Patients Have Better Drug-Survival Rate When Abatacept Is the First or Second Line Biologic Agent with an Excellent Overall Safety Profile: A Single Center Experience
Irini Flouri¹, Argyro Repa², Antonis Fanouriakis², Nikolaos Kougkas², Ioannis Papalopoulos², Eleni Kampouraki², Dimitrios Boumpas³, Nestor Avgoustidis², George Bertsias² and Prodromos Sidiropoulos², ¹Rheumatology, Clinical Immunology, Allergy, University of Crete, Medical School, University Hospital, Heraklion, Greece, ²Rheumatology, Clinical Immunology, and Allergy, University of Crete, Medical School, University Hospital, Heraklion, Greece, ³Biomedical Research Foundation, Academy of Athens, Athens, Greece
Background/Purpose: Long-term prospective observational studies are complementary to controlled clinical trials in exploring the effectiveness and safety of biological therapies in rheumatoid arthritis (RA). We…
Abstract Number: 2491 • 2014 ACR/ARHP Annual Meeting
Prognostic Factors for IV Abatacept Retention in Patients Who Have Received at Least One Prior Biologic Agent: 2-Year Results from a Prospective, International, Real-World Study
H Nüßlein¹, R Alten², M Galeazzi³, HM Lorenz⁴, MT Nurmohamed⁵, WG Bensen⁶, Gerd Burmester⁷, H-H Peter⁸, P Peichl⁹, K Pavelka¹⁰, M Chartier¹¹, C Poncet¹², C Rauch¹³ and M Le Bars¹⁴, ¹Internistische Schwerpunktpraxis, Nürnberg, Germany, ²Schlosspark-Klinik University Medicine, Berlin, Germany, ³University of Siena, Siena, Italy, ⁴University Hospital, Heidelberg, Germany, ⁵VU Univ Medical Center/Jan van Breeman Research Institute, Amsterdam, Netherlands, ⁶St Josephs Hospital and McMaster University, Hamilton, ON, Canada, ⁷Charité-Universitätsmedizin, Berlin, Germany, ⁸University of Freiburg, Freiburg, Germany, ⁹Evangelisches Krankenhaus, Vienna, Austria, ¹⁰Institute of Rheumatology, Prague, Czech Republic, ¹¹Chiltern International, Neuilly, France, ¹²Docs International, Nanterre, France, ¹³Bristol-Myers Squibb, Munich, Germany, ¹⁴Bristol-Myers Squibb, Rueil-Malmaison, France
Background/Purpose: To identify prognostic factors of retention for abatacept (ABA) treatment in patients (pts) with moderate-to-severe RA, using final results from the real-world ACTION study.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].